

Atty. Dkt. No. 041673-2115

**Amendments to the Claims:**

The claims are not being amended herein. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for delivery of a therapeutic neurotrophin to targeted neurotrophin-receptive neurons in the mammalian brain to stimulate growth or sustain activity therein, the method comprising delivering a neurotrophin encoding transgene into two or more delivery sites in the brain, wherein each delivery site is no more than about 10 mm from another delivery site.
2. (Original) The method according to Claim 1, wherein the transgene is expressed by a viral expression vector.
3. (Original) The method according to Claim 2, wherein the viral expression vector is an adenovirus.
4. (Original) The method according to Claim 2, wherein the viral expression vector is an adeno-associated virus.
5. (Original) The method according to Claim 2, wherein the viral expression vector is a lentivirus.
6. (Original) The method according to Claim 2, wherein the viral expression vector is HIV-1.
7. (Original) The method according to Claim 2, wherein the neurotrophic composition is a fluid having a concentration of neurotrophin encoding viral particles in the range from  $10^{10}$  to  $10^{15}$  particles per ml of neurotrophic composition.
8. (Original) The method according to Claim 7, wherein from 2.5  $\mu$ l to 25  $\mu$ l of the neurotrophic composition is delivered to each delivery site.
9. (Cancelled).

Atty. Dkt. No. 041673-2115

10. (Cancelled).
11. (Original) The method according to Claim 1 wherein the treated mammal is a human and the transgene encodes a human neurotrophin.
12. (Previously Presented) The method according to Claim 11 wherein the neurotrophin is selected from the group of neurotrophins consisting of human beta nerve growth factor ( $\beta$ -NGF); human neurotrophin 3 (NT-3); glial cell line-derived neurotrophic factor (GDNF); brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5).
13. (Cancelled).
14. (Original) The method according to Claim 1 wherein the delivery sites are intraparenchymal.
15. (Original) The method according to Claim 1 wherein the delivery sites are within the Ch4 region of the cholinergic basal forebrain.
16. (Original) The method according to Claim 1 wherein the transgene is expressed by a non-viral expression vector.
17. (Previously Presented) The method according to Claim 11 wherein the growth or increase in neuronal activity ameliorates Alzheimer's disease in the human.
18. (Previously Presented) The method according to Claim 11 wherein the growth or increase in activity ameliorates Parkinson's Disease in the human.